A Phase 1 interventional study of NNC 0141-0000-0100 and placebo in Inflammation and Rheumatoid Arthritis, sponsored by Innate Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-12-23.
Sponsored by Innate Pharma · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 361 studies in Arthritis, Rheumatoid with a site in Germany — 26 open to participants now, 49 under way, 3 of them phase 3. Arthritis, Rheumatoid · Germany.
Among the 361 studies in Arthritis, Rheumatoid with a site in Germany, this one is the 224th largest by enrollment of the 296 interventional ones that give a count, is one of 21 that started in 2011, is one of 34 in phase 1, and was the 132nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →26 of the 361 studies in Arthritis, Rheumatoid with a site in Germany are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Germany, United States, Belgium and 8 more countries
Ages 18–65
Quell Therapeutics Limited · Sites in Germany, Spain, United Kingdom
Ages 18+
AstraZeneca · Sites in Germany, United States, Australia and 3 more countries
Ages 18–75
AstraZeneca · Sites in Germany, United States, Argentina and 14 more countries
Ages 18+
Hoffmann-La Roche · Sites in Germany, United States, Argentina and 9 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
361 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 107 · Phase 3 116 · Phase 4 22
First in 1998; this study’s year is marked. 21 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 92 is close to the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 262 across the 296 interventional studies, 585 across the 65 observational. Of the 305 that completed or were terminated, 198 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
326 of 361 have an industry lead sponsor. The 10 most frequent:
Innate Pharma is the lead sponsor of 17 studies on the registry; 1 is open to participants now.
Innate Pharma has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
13 of the studies in Arthritis, Rheumatoid with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02337244Zimmer, GmbHZimmer POLAR Persona - TKA (EMEA Study) | 2026-12 |
| NCT06972446AbbVieA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | 2027-02 |
| NCT06831994Universitätsklinikum Hamburg-EppendorfDigital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity | 2027-02-28 |
| NCT06902519Gilead SciencesStudy of GS-0151 in Participants With Rheumatoid Arthritis | 2027-03 |
| NCT07137598Hoffmann-La RocheA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | 2027-04-17 |
Add all 13 to your calendar (.ics) → With an account.
Among the 361 studies in Arthritis, Rheumatoid with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Europe. The aim of this dose-escalating trial is to assess the safety, tolerability, pharmacokinetics (the rate at which the body eliminates the trial drug) and pharmacodynamics (the effect of the investigated drug on the body) of single and repeated doses of NNC141-0100 in subjects with Rheumatoid Arthritis.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
This study's enrollment of 92 is close to the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Browse Arthritis, Rheumatoid studies →Innate Pharma is the lead sponsor of 17 studies on the registry; 1 is open to participants now.
Compared within Arthritis, Rheumatoid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammation. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: NNC 0141-0000-0100 · Drug: placebo
Drug: NNC 0141-0000-0100 · Drug: placebo
Drug: NNC 0141-0000-0100 · Drug: placebo
Single dose administered subcutaneously (under the skin), up to six dose levels. Progression to next dose will be based on safety evaluation. Initiation of the MD s.c. phase will depend on the results from the SD i.v. cohorts as well as the first two dose cohorts of the SD s.c. part
Single dose administered subcutaneously (under the skin) as a comparator at all dose levels
Multiple doses administered subcutaneously (under the skin) at 4 different occasions with a dosing interval of two weeks, at five different dose levels.
Multiple doses administered subcutaneously (under the skin) as a comparator at all dose levels
Single dose administered intravenously (into a vein), up to nine dose levels. Progression to next dose will be based on safety evaluation. Initiation of the SD s.c. phase will depend on the results from the first three dose cohorts of the SD i.v. part
Single dose administered intravenously (into a vein), as a comparator at all dose levels
Incidence of adverse events
Time frame: from trial product administration to week 12
Antibodies against NNC141-0100
Time frame: from trial product administration until final visit (week 12 or longer if applicable)
Area under the serum concentration-time curve - SD trial part
Time frame: from trial product administration until final visit (week 12 or longer if applicable)
Terminal half-life (t½) - SD trial part
Time frame: from trial product administration until final visit (week 12 or longer if applicable)
Terminal half-life (t½) - MD trial part
Time frame: from trial product administration until final visit (week 12 or longer if applicable)
The record gives a start of May 2011, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Monalizumab
Innate Pharma